Temporal changes in cardiac matrix metalloproteinase activity, oxidative stress, and TGF-β in renovascular hypertension-induced cardiac hypertrophy

Experimental and Molecular Pathology

Volumn 94, Issue 1, 2013, Pages 1-9

  Rizzi, Elen ^a   Ceron, Carla S ^a   Guimaraes, Danielle A ^a   Prado, Cibele M ^a   Rossi, Marcos A ^a   Gerlach, Raquel F ^a   Tanus Santos, Jose E ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Cardiac hypertrophy; Matrix metalloproteinases; Reactive oxygen species; Renovascular hypertension

Indexed keywords

COLLAGEN; GELATINASE A; HYDROETHIDINE; MATRIX METALLOPROTEINASE; REACTIVE OXYGEN METABOLITE; TISSUE INHIBITOR OF METALLOPROTEINASE 4; TRANSFORMING GROWTH FACTOR BETA;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; FIBROSIS; HEART VENTRICLE HYPERTROPHY; HEART VENTRICLE REMODELING; HYPERTENSION; IMMUNOFLUORESCENCE TEST; MALE; MORPHOMETRICS; NONHUMAN; OXIDATIVE STRESS; RAT; RENOVASCULAR HYPERTENSION INDUCED CARDIAC HYPERTROPHY; SYSTOLIC BLOOD PRESSURE; ZYMOGRAPHY;

ANIMALS; BLOOD PRESSURE; CARDIOMEGALY; COLLAGEN; FIBROSIS; HEART; HEART VENTRICLES; HYPERTENSION, RENOVASCULAR; MALE; MATRIX METALLOPROTEINASE 2; MYOCARDIUM; OXIDATIVE STRESS; RATS; RATS, WISTAR; REACTIVE OXYGEN SPECIES; TISSUE INHIBITOR OF METALLOPROTEINASES; TRANSFORMING GROWTH FACTOR BETA;

RATTUS;

EID: 84870920351     PISSN: 00144800     EISSN: 10960945     Source Type: Journal    
DOI: 10.1016/j.yexmp.2012.10.010     Document Type: Article

References (44)

1. Baker K.M., Aceto J.F. Angiotensin II stimulation of protein synthesis and cell growth in chick heart cells. American Journal of Physiology 1990, 259:H610-H618.
2. Bergman M.R., Teerlink J.R., Mahimkar R., Li L., Zhu B.Q., Nguyen A., Dahi S., Karliner J.S., Lovett D.H. Cardiac matrix metalloproteinase-2 expression independently induces marked ventricular remodeling and systolic dysfunction. American Journal of Physiology. Heart and Circulatory Physiology 2007, 292:H1847-H1860.
3. Berk B.C., Fujiwara K., Lehoux S. ECM remodeling in hypertensive heart disease. The Journal of Clinical Investigation 2007, 117:568-575.
4. Bigg H.F., Shi Y.E., Liu Y.E., Steffensen B., Overall C.M. Specific, high affinity binding of tissue inhibitor of metalloproteinases-4 (TIMP-4) to the COOH-terminal hemopexin-like domain of human gelatinase A. TIMP-4 binds progelatinase A and the COOH-terminal domain in a similar manner to TIMP-2. Journal of Biological Chemistry 1997, 272:15496-15500.
5. Buzello M., Boehm C., Orth S., Fischer B., Ehmke H., Ritz E., Mall G., Amann K. Myocyte loss in early left ventricular hypertrophy of experimental renovascular hypertension. Virchows Archiv 2003, 442:364-371.
6. Castro M.M., Rizzi E., Figueiredo-Lopes L., Fernandes K., Bendhack L.M., Pitol D.L., Gerlach R.F., Tanus-Santos J.E. Metalloproteinase inhibition ameliorates hypertension and prevents vascular dysfunction and remodeling in renovascular hypertensive rats. Atherosclerosis 2008, 198:320-331.
7. Castro M.M., Rizzi E., Rodrigues G.J., Ceron C.S., Bendhack L.M., Gerlach R.F., Tanus-Santos J.E. Antioxidant treatment reduces matrix metalloproteinase-2-induced vascular changes in renovascular hypertension. Free Radical Biology & Medicine 2009, 46:1298-1307.
8. Castro M.M., Rizzi E., Prado C.M., Rossi M.A., Tanus-Santos J.E., Gerlach R.F. Imbalance between matrix metalloproteinases and tissue inhibitor of metalloproteinases in hypertensive vascular remodeling. Matrix Biology 2010, 29:194-201.
9. Clark I.M., Swingler T.E., Sampieri C.L., Edwards D.R. The regulation of matrix metalloproteinases and their inhibitors. The International Journal of Biochemistry & Cell Biology 2008, 40:1362-1378.
10. Doggrell S.A., Brown L. Rat models of hypertension, cardiac hypertrophy and failure. Cardiovascular Research 1998, 39:89-105.
11. Donnini S., Monti M., Roncone R., Morbidelli L., Rocchigiani M., Oliviero S., Casella L., Giachetti A., Schulz R., Ziche M. Peroxynitrite inactivates human-tissue inhibitor of metalloproteinase-4. FEBS Letters 2008, 582:1135-1140.
12. Ehmke H., Faulhaber J., Munter K., Kirchengast M., Wiesner R.J. Chronic ETA receptor blockade attenuates cardiac hypertrophy independently of blood pressure effects in renovascular hypertensive rats. Hypertension 1999, 33:954-960.
13. Fanjul-Fernandez M., Folgueras A.R., Cabrera S., Lopez-Otin C. Matrix metalloproteinases: evolution, gene regulation and functional analysis in mouse models. Biochimica et Biophysica Acta 2010, 1803:3-19.
14. Gajarsa J.J., Kloner R.A. Left ventricular remodeling in the post-infarction heart: a review of cellular, molecular mechanisms, and therapeutic modalities. Heart Failure Reviews 2011, 16:13-21.
15. Hocher B., Godes M., Olivier J., Weil J., Eschenhagen T., Slowinski T., Neumayer H.H., Bauer C., Paul M., Pinto Y.M. Inhibition of left ventricular fibrosis by tranilast in rats with renovascular hypertension. Journal of Hypertension 2002, 20:745-751.
16. Iwanaga Y., Aoyama T., Kihara Y., Onozawa Y., Yoneda T., Sasayama S. Excessive activation of matrix metalloproteinases coincides with left ventricular remodeling during transition from hypertrophy to heart failure in hypertensive rats. Journal of the American College of Cardiology 2002, 39:1384-1391.
17. Kandalam V., Basu R., Moore L., Fan D., Wang X., Jaworski D.M., Oudit G.Y., Kassiri Z. Lack of tissue inhibitor of metalloproteinases 2 leads to exacerbated left ventricular dysfunction and adverse extracellular matrix remodeling in response to biomechanical stress. Circulation 2011, 124:2094-2105.
18. Kandasamy A.D., Chow A.K., Ali M.A., Schulz R. Matrix metalloproteinase-2 and myocardial oxidative stress injury: beyond the matrix. Cardiovascular Research 2009, 20:20.
19. Liu R.M., Gaston Pravia K.A. Oxidative stress and glutathione in TGF-beta-mediated fibrogenesis. Free Radical Biology & Medicine 2010, 48:1-15.
20. Lopez B., Gonzalez A., Querejeta R., Larman M., Diez J. Alterations in the pattern of collagen deposition may contribute to the deterioration of systolic function in hypertensive patients with heart failure. Journal of the American College of Cardiology 2006, 48:89-96.
21. Luchtefeld M., Grote K., Grothusen C., Bley S., Bandlow N., Selle T., Struber M., Haverich A., Bavendiek U., Drexler H., Schieffer B. Angiotensin II induces MMP-2 in a p47phox-dependent manner. Biochemical and Biophysical Research Communications 2005, 328:183-188.
22. Matsusaka H., Ide T., Matsushima S., Ikeuchi M., Kubota T., Sunagawa K., Kinugawa S., Tsutsui H. Targeted deletion of matrix metalloproteinase 2 ameliorates myocardial remodeling in mice with chronic pressure overload. Hypertension 2006, 47:711-717.
23. Moore L., Fan D., Basu R., Kandalam V., Kassiri Z. Tissue inhibitor of metalloproteinases (TIMPs) in heart failure. Heart Failure Reviews 2012, 17:693-706.
24. Odenbach J., Wang X., Cooper S., Chow F.L., Oka T., Lopaschuk G., Kassiri Z., Fernandez-Patron C. MMP-2 mediates angiotensin II-induced hypertension under the transcriptional control of MMP-7 and TACE. Hypertension 2011, 57:123-130.
25. Okamoto T., Akaike T., Sawa T., Miyamoto Y., van der Vliet A., Maeda H. Activation of matrix metalloproteinases by peroxynitrite-induced protein S-glutathiolation via disulfide S-oxide formation. Journal of Biological Chemistry 2001, 276:29596-29602.
26. Opie L.H., Commerford P.J., Gersh B.J., Pfeffer M.A. Controversies in ventricular remodelling. Lancet 2006, 367:356-367.
27. Rizzi E., Castro M.M., Prado C.M., Silva C.A., Fazan R., Rossi M.A., Tanus-Santos J.E., Gerlach R.F. Matrix metalloproteinase inhibition improves cardiac dysfunction and remodeling in 2-kidney, 1-clip hypertension. Journal of Cardiac Failure 2010, 16:599-608.
28. Rizzi E., Castro M.M., Ceron C.S., Neto-Neves E.M., Prado C.M., Rossi M.A., Tanus-Santos J.E., Gerlach R.F. Tempol inhibits TGF-beta and MMPs upregulation and prevents cardiac hypertensive changes. International Journal of Cardiology. 2011, 10.1016/j.ijcard.2011.08.060.
29. Rosenkranz S. TGF-beta1 and angiotensin networking in cardiac remodeling. Cardiovascular Research 2004, 63:423-432.
30. Rossi M.A. Pathologic fibrosis and connective tissue matrix in left ventricular hypertrophy due to chronic arterial hypertension in humans. Journal of Hypertension 1998, 16:1031-1041.
31. Rossi M.A., Peres L.C. Effect of captopril on the prevention and regression of myocardial cell hypertrophy and interstitial fibrosis in pressure overload cardiac hypertrophy. American Heart Journal 1992, 124:700-709.
32. Sadoshima J., Izumo S. Molecular characterization of angiotensin II-induced hypertrophy of cardiac myocytes and hyperplasia of cardiac fibroblasts. Critical role of the AT1 receptor subtype. Circulation Research 1993, 73:413-423.
33. Schultz Jel J., Witt S.A., Glascock B.J., Nieman M.L., Reiser P.J., Nix S.L., Kimball T.R., Doetschman T. TGF-beta1 mediates the hypertrophic cardiomyocyte growth induced by angiotensin II. The Journal of Clinical Investigation 2002, 109:787-796.
34. Schulz R. Intracellular targets of matrix metalloproteinase-2 in cardiac disease: rationale and therapeutic approaches. Annual Review of Pharmacology and Toxicology 2007, 47:211-242.
35. Sorescu D., Griendling K.K. Reactive oxygen species, mitochondria, and NAD(P)H oxidases in the development and progression of heart failure. Congestive Heart Failure 2002, 8:132-140.
36. Sousa-Santos O., Neto-Neves E.M., Ferraz K.C., Ceron C.S., Rizzi E., Gerlach R.F., Tanus-Santos J.E. Antioxidant treatment protects against matrix metalloproteinase activation and cardiomyocyte injury during acute pulmonary thromboembolism. Naunyn-Schmiedeberg's Archives of Pharmacology 2012, 385:685-696.
37. Spinale F.G. Matrix metalloproteinases: regulation and dysregulation in the failing heart. Circulation Research 2002, 90:520-530.
38. Spinale F.G. Myocardial matrix remodeling and the matrix metalloproteinases: influence on cardiac form and function. Physiological Reviews 2007, 87:1285-1342.
39. Spinale F.G., Coker M.L., Bond B.R., Zellner J.L. Myocardial matrix degradation and metalloproteinase activation in the failing heart: a potential therapeutic target. Cardiovascular Research 2000, 46:225-238.
40. Tozzi R., Palladini G., Fallarini S., Nano R., Gatti C., Presotto C., Schiavone A., Micheletti R., Ferrari P., Fogari R., Perlini S. Matrix metalloprotease activity is enhanced in the compensated but not in the decompensated phase of pressure overload hypertrophy. American Journal of Hypertension 2007, 20:663-669.
41. Tsutsui H., Kinugawa S., Matsushima S. Oxidative stress and heart failure. American Journal of Physiology. Heart and Circulatory Physiology 2011, 301:H2181-H2190.
42. Viappiani S., Nicolescu A.C., Holt A., Sawicki G., Crawford B.D., Leon H., van Mulligen T., Schulz R. Activation and modulation of 72kDa matrix metalloproteinase-2 by peroxynitrite and glutathione. Biochemical Pharmacology 2009, 77:826-834.
43. Wenzel S., Taimor G., Piper H.M., Schluter K.D. Redox-sensitive intermediates mediate angiotensin II-induced p38 MAP kinase activation, AP-1 binding activity, and TGF-beta expression in adult ventricular cardiomyocytes. The FASEB Journal 2001, 15:2291-2293.
44. Zhao W., Zhao T., Chen Y., Ahokas R.A., Sun Y. Oxidative stress mediates cardiac fibrosis by enhancing transforming growth factor-beta1 in hypertensive rats. Molecular and Cellular Biochemistry 2008, 317:43-50.